Literature DB >> 18057521

The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary.

Kwong-Kwok Wong1, David Gershenson.   

Abstract

The role of serous tumors of low malignant potential (LMP) in the development of invasive epithelial cancer of the ovary is debatable. This review summarizes the current clinical, genetic, and genomic evidence for the existence of a continuum comprising both LMP serous tumors and low-grade serous ovarian carcinomas.

Entities:  

Mesh：

Year:  2007        PMID： 18057521      PMCID： PMC3850577          DOI： 10.1155/2007/204715

Source DB:  PubMed          Journal:  Dis Markers        ISSN： 0278-0240            Impact factor:   3.434


  12 in total

Review 1.  Low-grade Serous Tumors: Are We Making Progress?

Authors:  Nina Pauly; Sarah Ehmann; Enzo Ricciardi; Beyhan Ataseven; Mareike Bommert; Florian Heitz; Sonia Prader; Stephanie Schneider; Andreas du Bois; Philipp Harter; Thaïs Baert
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

2.  Peritoneal washing cytologic analysis of ovarian serous tumors of low malignant potential to detect peritoneal implants and predict clinical outcome.

Authors:  Nour Sneige; John B Thomison; Anais Malpica; Yun Gong; Joe Ensor; Elvio G Silva
Journal:  Cancer Cytopathol       Date:  2012-07-23       Impact factor: 5.284

3.  Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium.

Authors:  Linda E Kelemen; Marc T Goodman; Valerie McGuire; Mary Anne Rossing; Penelope M Webb; Martin Köbel; Hoda Anton-Culver; Jonathan Beesley; Andrew Berchuck; Sony Brar; Michael E Carney; Jenny Chang-Claude; Georgia Chenevix-Trench; Daniel W Cramer; Julie M Cunningham; Richard A Dicioccio; Jennifer A Doherty; Douglas F Easton; Zachary S Fredericksen; Brooke L Fridley; Margaret A Gates; Simon A Gayther; Aleksandra Gentry-Maharaj; Estrid Høgdall; Susanne Krüger Kjaer; Galina Lurie; Usha Menon; Patricia G Moorman; Kirsten Moysich; Roberta B Ness; Rachel T Palmieri; Celeste L Pearce; Paul D P Pharoah; Susan J Ramus; Honglin Song; Daniel O Stram; Shelley S Tworoger; David Van Den Berg; Robert A Vierkant; Shan Wang-Gohrke; Alice S Whittemore; Lynne R Wilkens; Anna H Wu; Joellen M Schildkraut; Thomas A Sellers; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-06-22       Impact factor: 4.254

4.  The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.

Authors:  Erin R King; Celestine S Tung; Yvonne T M Tsang; Zhifei Zu; Gabriel T M Lok; Michael T Deavers; Anais Malpica; Judith K Wolf; Karen H Lu; Michael J Birrer; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

5.  BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

Authors:  Kwong-Kwok Wong; Yvonne T M Tsang; Michael T Deavers; Samuel C Mok; Zhifei Zu; Charlotte Sun; Anais Malpica; Judith K Wolf; Karen H Lu; David M Gershenson
Journal:  Am J Pathol       Date:  2010-08-27       Impact factor: 4.307

6.  KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Authors:  Yvonne T Tsang; Michael T Deavers; Charlotte C Sun; Suet-Yan Kwan; Eric Kuo; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

7.  Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.

Authors:  Koji Matsuo; Hiroko Machida; Brendan H Grubbs; Shinya Matsuzaki; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson
Journal:  Gynecol Oncol       Date:  2020-01-15       Impact factor: 5.482

8.  Differentially methylated loci distinguish ovarian carcinoma histological types: evaluation of a DNA methylation assay in FFPE tissue.

Authors:  Linda E Kelemen; Martin Köbel; Angela Chan; Soreh Taghaddos; Irina Dinu
Journal:  Biomed Res Int       Date:  2013-09-24       Impact factor: 3.411

9.  Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium.

Authors:  Linda E Kelemen; Elisa V Bandera; Kathryn L Terry; Mary Anne Rossing; Louise A Brinton; Jennifer A Doherty; Roberta B Ness; Susanne Krüger Kjaer; Jenny Chang-Claude; Martin Köbel; Galina Lurie; Pamela J Thompson; Michael E Carney; Kirsten Moysich; Robert Edwards; Clare Bunker; Allan Jensen; Estrid Høgdall; Daniel W Cramer; Allison F Vitonis; Sara H Olson; Melony King; Urmila Chandran; Jolanta Lissowska; Montserrat Garcia-Closas; Hannah Yang; Penelope M Webb; Joellen M Schildkraut; Marc T Goodman; Harvey A Risch
Journal:  BMC Cancer       Date:  2013-01-22       Impact factor: 4.430

10.  Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.

Authors:  Laurie L Brunette; Paulette Y Mhawech-Fauceglia; Lingyun Ji; Joseph G Skeate; Heike E Brand; Kate Lawrenson; Saloni Walia; Maurizio Chiriva-Internati; Susan Groshen; Lynda D Roman; W Martin Kast; Diane M Da Silva
Journal:  BMC Cancer       Date:  2018-10-11       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.